• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Hurwitz Edward

    6/3/25 9:41:10 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    HURWITZ EDWARD

    (Last) (First) (Middle)
    C/O DYNE THERAPEUTICS, INC.
    1560 TRAPELO ROAD

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Dyne Therapeutics, Inc. [ DYN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/30/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock option (right to buy) $11.96 05/30/2025 A 35,000 (1) 05/29/2035 Common Stock 35,000 $0.00 35,000 D
    Explanation of Responses:
    1. This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.
    Remarks:
    Exhibit Index: 24.1 Power of Attorney
    /s/ Ron Caponigro, Attorney-in-Fact 06/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DYN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    3/7/2025$50.00Sector Outperform
    Scotiabank
    12/13/2024$46.00Outperform
    Robert W. Baird
    11/26/2024$45.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bernstein initiated coverage on Dyne Therapeutics with a new price target

      Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00

      6/24/25 8:00:58 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Dyne Therapeutics with a new price target

      Raymond James resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $37.00

      6/11/25 7:53:49 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Dyne Therapeutics with a new price target

      Oppenheimer resumed coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00

      6/2/25 8:51:54 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & President Cox John bought $1,057,216 worth of shares (32,000 units at $33.04) (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      9/4/24 5:42:18 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kersten Dirk bought $29,999,988 worth of shares (1,714,285 units at $17.50) (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      1/11/24 4:31:55 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    SEC Filings

    See more
    • SEC Form 424B5 filed by Dyne Therapeutics Inc.

      424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)

      6/30/25 4:43:07 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

      6/30/25 4:01:19 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

      6/17/25 7:04:28 AM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CEO & President Cox John sold $54,201 worth of shares (4,060 units at $13.35), decreasing direct ownership by 3% to 142,179 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:07:07 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Kerr Douglas sold $17,916 worth of shares (1,342 units at $13.35), decreasing direct ownership by 1% to 92,815 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:05:18 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Friedl-Naderer Johanna sold $1,949 worth of shares (146 units at $13.35), decreasing direct ownership by 0.15% to 95,911 units (SEC Form 4)

      4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

      6/6/25 4:03:04 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

      WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditi

      6/30/25 9:45:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Announces Proposed Public Offering of Common Stock

      WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $200,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne. Morgan Stanley, Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering. Jones is acting as co-manager for

      6/30/25 4:05:00 PM ET
      $DYN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital

      - $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction strengthens the company's balance sheet as it advances DYNE-101 and DYNE-251

      6/30/25 4:01:00 PM ET
      $DYN
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance